IP Library Patent Application 14960344
Patent Application
App. No. 14/960,344

Method and System for Treatment of Damaged Biological Tissue

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/960,344
Abstract

Biomaterial compositions and articles comprising mesothelial tissue and a glycosaminoglycan (GAG), for treating damaged biological tissue; particularly, damaged cardiovascular tissue. The biomaterial compositions and articles can also include additional biologically active agents, such as growth factors. The biomaterial compositions and articles induce modulated healing, including modulation of inflammation and induced neovascularization when administered to damaged biological tissue.

Claims (6)

1 . A composition for treating damaged biological tissue, comprising:

an extracellular matrix (ECM) composition comprising acellular mesothelial tissue and a supplemental biologically active agent, said supplemental biologically active agent comprising a glycosaminoglycan (GAG), wherein, when said ECM composition is administered to said damaged biological tissue, said ECM composition induces modulated healing, said modulated healing comprising modulation of inflammation and induced bioremodeling and regeneration of new biological tissue.

2 . The composition of claim 1 , wherein said ECM composition further comprises an exogenously added growth factor selected from the group consisting of transforming growth factor beta (TGF-beta), fibroblast growth factor-2 (FGF-2) and vascular epithelial growth factor (VEGF).

3 . The composition of claim 1 , wherein said ECM composition further comprises a statin selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin.

4 . The composition of claim 1 , wherein said ECM composition further comprises a pharmacological agent.

5 . The composition of claim 4 , wherein said pharmacological agent comprises an agent selected from the group consisting of an anti-viral agent, analgesic, antibiotic, anti-inflammatory, anti-neoplastic, anti-spasmodic, enzyme and enzyme inhibitor, anticoagulant and/or antithrombic agent, and vasodilating agent.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 21, 2015
From: MATHENY, ROBERT G
To: CORMATRIX CARDIOVASCULAR, INC.
Reel/Frame 037339/0671 →